



Synonym


IL-17A, Interleukin-17A, CTLA-8, IL-17

Source

Human IL-17A Protein, His Tag(ILA-H5243) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - Ala 155 (Accession # [Q16552-1](#)).

Predicted N-terminus: His

Molecular Characterization



This protein carries a polyhistidine tag at the N-terminus.

The protein has a calculated MW of 17.0 kDa. The protein migrates as 17-20 kDa and 22-25 kDa when calibrated against [Star Ribbon Pre-stained Protein Marker](#) under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per µg by the LAL method.

Purity

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

Formulation

Lyophilized from 0.22 µm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.


SDS-PAGE



Human IL-17A Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With [Star Ribbon Pre-stained Protein Marker](#)).

Bioactivity-ELISA

SEC-MALS




The purity of Human IL-17A Protein, His Tag (Cat. No. ILA-H5243) is more than 90% and the molecular weight of this protein is around 35-45 kDa verified by SEC-MALS.

[Report](#)

Discounts, Gifts,
and more!





Immobilized Human IL-17A Protein, His Tag (Cat. No. ILA-H5243) at 5 µg/mL (100 µL/well) can bind Monoclonal Anti-Human IL17A Antibody, Human IgG1 with a linear range of 0.2-2 ng/mL (QC tested).

Background

Interleukin-17A (IL-17A), also known as CTLA-8, is a 15-20 kDa glycosylated cytokine that plays an important role in anti-microbial and chronic inflammation. The six IL-17 cytokines (IL-17A-F) are encoded by separate genes but adopt a conserved cystine knot fold (1, 2). Mature cynomolgus monkey IL-17A shares 96% amino acid sequence identity with human IL-17A (3, 4). IL-17A is secreted by Th17 cells, gamma /δ T cells, iNKT cells, NK cells, LTi cells, neutrophils, and intestinal Paneth cells (2). It forms disulfide-linked homodimers as well as disulfide-linked heterodimers with IL-17F (5, 6). IL-17A exerts its effects through the transmembrane IL-17RA in complex with IL-17RC or IL-17RD (7, 8). Both IL-17RA and IL-17RC are required for responsiveness to heterodimeric IL-17A/F (7). IL-17A promotes protective mucosal and epidermal inflammation in response to microbial infection (9-12). It induces chemokine production, neutrophil influx, and the production of antibacterial peptides (9-11). IL-17A/F likewise induces neutrophil migration, but IL-17F does not (11). IL-17A additionally enhances the production of inflammatory mediators by rheumatoid synovial fibroblasts and contributes to TNF-alpha induced shock (4, 13). In contrast, it can protect against the progression of colitis by limiting chronic inflammation (12). IL-17A encourages the formation of autoreactive germinal centers and exacerbates the onset and progression of experimental models of autoimmunity (14, 15). IL-17A has been shown to exert either tumorigenic or anti-tumor effects (16, 17).

Clinical and Translational Updates

Discounts, Gifts,
and more!

